BDPT on OTC
BIOADAPTIVES, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with PRF Technologies Ltd., SKINVISIBLE, INC. or Phio Pharmaceuticals Corp., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
68.4%Gross margin3
-5701.8%Operating margin3
-8523.4%Net margin3
44.3%Revenue growth, 20253
-$534.0KFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue8¢$5.8K
- Interest92¢$70.9K
Out of $18.3K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $18.3K | $12.7K |
| Cost of revenue | $5.8K | $8.6K |
| Gross Profit | $12.5K | $4.0K |
| General and administrative | $820.5K | $335.3K |
| Professional fees | $230.2K | $169.5K |
| Impairment of inventory | $0 | $81.3K |
| Amortization and impairment loss of license and patent | $4.0K | $19.9K |
| Total Operating Expenses | $1.1M | $606.1K |
| Loss from operations | -$1.0M | -$602.1K |
| Other income | $0 | $5.0K |
| Interest expense | -$70.9K | -$92.0K |
| Change in fair value of derivative liabilities | -$578.6K | -$210.0K |
| Loss on settlement of debt | $133.8K | $0 |
| Total Other Income (Expense) | -$515.7K | -$297.1K |
| Loss before income taxes | -$1.6M | -$899.2K |
| Net Loss | -$1.6M | -$899.2K |
| Basic and Diluted | -$0.15 | -$0.11 |
| Basic and Diluted | 10.1M shares | 8.2M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $158.4K | $137.5K | $60.8K |
| Inventory | $44.7K | $19.1K | |
| Security deposit | $2.5K | $2.5K | |
| Prepaid expense | $6.2K | $100.0K | |
| Other receivable | $0 | $2.8K | |
| Total Current Assets | $211.9K | $261.9K | |
| License and patent, net | $14.0K | $0 | |
| TOTAL ASSETS | $225.9K | $261.9K | |
| Accounts payable and accrued liabilities | $232.7K | $179.5K | |
| Derivative liabilities | $1.7M | $1.1M | |
| Convertible notes | $352.3K | $461.0K | |
| Notes Payable | $32.1K | $32.1K | |
| Total Current Liabilities | $2.4M | $1.7M | |
| Total Liabilities | $2.4M | $1.7M | |
| Common stock ($.0001 par value, 1,250,000,000 shares authorized; 12,008,725 and 8,215,426 shares issued and outstanding as of December 31, 2025 and 2024, and 66 issuable, respectively) | $1.2K | $821 | |
| Additional paid-in capital | $8.6M | $7.7M | |
| Subscription receivable | -$5.9K | -$5.9K | |
| Accumulated deficit | -$10.7M | -$9.2M | |
| Total Stockholders' Deficit | -$2.1M | -$1.5M | -$1.6M |
| Liabilities and Equity | $225.9K | $261.9K | |
| Preferred stock, shares par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 31.0M shares | 31.0M shares | |
| Common stock, shares par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.2B shares | 1.2B shares | |
| Common stock, shares issued | 12.0M shares | 8.2M shares | |
| Common stock, shares outstanding | 12.0M shares | 8.2M shares | |
| Common stock, shares issuable | 66 shares | 66 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$1.6M | -$899.2K |
| Change in fair value of derivative liabilities | $578.6K | $210.0K |
| Bad debt | $2.9K | $0 |
| Impairment of patent | $0 | $18.0K |
| Impairment of inventory | $0 | $81.3K |
| Amortization of license and patent | $0 | $1.9K |
| Amortization of debt discount | $25.1K | $52.6K |
| Management compensation | $443.7K | $208.9K |
| Depreciation | $4.0K | $0 |
| Gain on settlement of debt | -$133.8K | $0 |
| Accounts receivable | -$59 | $0 |
| Inventory | -$25.6K | -$25.2K |
| Prepaid expense | $93.8K | $57.2K |
| Accounts payable and accrued liabilities | $53.3K | $44.8K |
| Net Cash Used in Operating Activities | -$516.0K | -$249.5K |
| Purchase property and equipment's | -$18.0K | $0 |
| Net Cash Used in Investing Activities | -$18.0K | $0 |
| Proceeds from issuance of Series D Preferred Stock | $300.0K | $294.1K |
| Proceeds from notes payable | $0 | $32.1K |
| Proceeds from convertible notes | $255.0K | $0 |
| Net Cash Provided by Financing Activities | $555.0K | $326.2K |
| Net change in cash | $21.0K | $76.7K |
| Cash paid for income taxes | $0 | $0 |
| Cash paid for interest | $0 | $0 |
| Derivative liability recognized as debt discount | $255.0K | $0 |
| Issuance of common stock for conversion of debt | $148.1K | $202.6K |
| Issuance of common stock for conversion of debt | $150.0K | $0 |
| Issuance of Series A preferred stock for license fee | $0 | $1.5K |
| Issuance of Series B preferred stock for license fee | $0 | $3.0K |
| Issuance of Series B preferred stock for settlement of debt - related party | $0 | $1.5K |
| Issuance of Series C preferred stock for license fee | $0 | $60.0K |
| Convertible note issued for consulting service | $0 | $150.0K |
| Debt forgiveness | $0 | $310.2K |
Former names
- APEX 8 Inc.May 3, 2013 to Aug 19, 20132
Recent filings
- Oct 6, 20264
- Sep 3, 20264
- Aug 19, 202610-Q
- Aug 14, 2026NT 10-Q
- Aug 4, 20264
- Jul 6, 20264
- Jun 3, 20264
- May 15, 202610-Q
- May 5, 20264
- Apr 14, 202610-K
- Apr 3, 20264
- Mar 31, 2026NT 10-K
- Mar 3, 20264
- Feb 3, 20264
- Jan 5, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10